Chen Chen, Jing Gao, Li Zhou, Juan Shi, Bin Cui, Jie Hong
From: 1. Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
2. Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrinology and Metabolism, China National Research Center for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Endocr Pract. 2017 Jul 6. doi: 10.4158/EP171849.OR.
Our study aimed to investigate glucose and lipid level as well as insulin resistance (IR) in patients with polycystic ovary syndrome (PCOS).
In a case-control study, 426 patients with PCOS were diagnosed according to Rotterdam criteria, and they were conducted in the morning after a 10-h fast. Participants received standard 75-g oral glucose tolerance test (OGTT). Plasma glucose and insulin levels were obtained at 0, 30, 60, 120, and 180 min. They also received the lipid evaluation; 95 healthy women with normal menstrual cycles served as controls. Thus, by modifying the homeostasis model assessment of insulin resistance (HOMA-IR) with the use of individual time-course values of glucose and insulin plasma levels, we developed a new assessment method, HOMA-Mx.
In our study, 23.71% of patients had abnormal glucose metabolism. With further impairment in glucose metabolism, the glucose and lipid level gradually increased (P<0.05), while the impaired glucose regulation (IGR) group showed greater insulin response than a type 2 diabetes mellitus (T2DM) group. Compared with healthy controls, both lean and obese PCOS patients with normal glucose tolerance (NGT) had a higher body mass index (BMI), and higher serum glucose, insulin, and lipid values. Additionally, the insulin value peaked at 30 min and 60 min in the lean and obese groups, respectively. HOMA-M30 proved to be the best predictive parameter (cutoff: 20.36, area under the curve [AUC]: 0.753) for assessment of IR in normal-weight patients and HOMA-IR (cutoff: 32.17, AUC: 0.868) was optimal in obese PCOS patients.
A new assessment method was developed for these groups: HOMA-M30 for lean PCOS patients and HOMA-M60 for obese patients, in order to focus on peak insulin values for early detection of IR.
我们的研究旨在调查多囊卵巢综合征(PCOS)患者的血糖和血脂水平以及胰岛素抵抗(IR)情况。
在一项病例对照研究中,426例PCOS患者根据鹿特丹标准进行诊断,且均在禁食10小时后的早晨进行检测。参与者接受标准的75克口服葡萄糖耐量试验(OGTT)。分别在0、30、60、120和180分钟时获取血浆葡萄糖和胰岛素水平。他们还接受了血脂评估;95名月经周期正常的健康女性作为对照。因此,通过利用葡萄糖和胰岛素血浆水平的个体时程值修改胰岛素抵抗的稳态模型评估(HOMA-IR),我们开发了一种新的评估方法,即HOMA-Mx。
在我们的研究中,23.71%的患者存在糖代谢异常。随着糖代谢进一步受损,血糖和血脂水平逐渐升高(P<0.05),而糖调节受损(IGR)组的胰岛素反应比2型糖尿病(T2DM)组更强。与健康对照相比,糖耐量正常(NGT)的瘦型和肥胖型PCOS患者的体重指数(BMI)更高,血清葡萄糖、胰岛素和血脂值也更高。此外,瘦型和肥胖型组的胰岛素值分别在30分钟和60分钟时达到峰值。HOMA-M30被证明是评估正常体重患者IR的最佳预测参数(截断值:20.36,曲线下面积[AUC]:0.753),而HOMA-IR(截断值:32.17,AUC:0.868)在肥胖型PCOS患者中是最佳的。
为这些群体开发了一种新的评估方法:瘦型PCOS患者采用HOMA-M30,肥胖患者采用HOMA-M60,以便关注胰岛素峰值以早期检测IR。